Notice2026-11996
Government Owned Inventions Available for License: 4-Amino-2-(Piperidin-3-yl)Isoindoline-1,3-Diones as Anti-Inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 15, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute on Aging (NIA) seeks research co- development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic degenerative and neurodegenerative disorders.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 114 (Monday, June 15, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 114 (Monday, June 15, 2026)]
[Notices]
[Page 35992]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-11996]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions Available for License: 4-Amino-2-
(Piperidin-3-yl)Isoindoline-1,3-Diones as Anti-Inflammatory Agents for
Systemic Degenerative and Neurodegenerative Disorders
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute on Aging (NIA) seeks research co-
development partners and/or licensees for the pre-clinical and clinical
development of the compounds as anti-inflammatory therapeutics for
systemic degenerative and neurodegenerative disorders.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this license
opportunity should be directed to: Nathan Whitman, Ph.D., Technology
Transfer Manager, NCI, Technology Transfer Center, Email:
<a href="/cdn-cgi/l/email-protection#a9c7c8ddc1c8c787dec1c0ddc4c8c7e9c7c0c187cec6df"><span class="__cf_email__" data-cfemail="9af4fbeef2fbf4b4edf2f3eef7fbf4daf4f3f2b4fdf5ec">[email protected]</span></a> or Phone: 240-276-6294.
SUPPLEMENTARY INFORMATION: The immunomodulatory imide drugs (IMiDs)
thalidomide and its close analogs (lenalidomide and pomalidomide) are
widely used to treat a variety of diseases--such as inflammatory
disorders, neurodegenerative diseases, multiple myeloma and other
cancers. However, thalidomide is poorly soluble in water and unstable--
complicating its delivery, bioavailability and subsequent evaluations.
Additionally, thalidomide is plagued by teratogenic adverse effects in
current human use. Therefore, there is intense interest in developing
analogs that exhibit suitable properties of solubility and stability
while retaining desirable biological activity safe for clinical use.
Researchers at the National Institute on Aging (NIA) have
synthesized a promising new family of IMiD compounds with improved
chemical stability, enhanced water solubility, and potent anti-
inflammatory properties. In cell-based studies, these compounds
significantly reduced key inflammation markers, including nitrate and
IL-6. Along with the ability to maintain high levels of cell viability,
these improvements positionthem as promising therapeutic candidates.
Unlike traditional IMiD drugs, these compounds do not bind to the
cereblon protein, eliminating concerns of teratogenicity. The compounds
also demonstrated a high binding affinity to the sigma and serotonin
receptors, both linked to cellular inflammation, which further enhances
their potential for treating neurodegenerative disorders, traumatic
brain injury, inflammatory disorders, viral infections and cancer.
``This Notice is in accordance with 37 CFR 404.4 Authority to grant
licenses.''
NIH Reference Number: E-183-2024.
Related Technologies: E-045-2012-0, E-208-2015-0, E-151-2022-0.
Product Type: Therapeutic.
Therapeutic Area(s): Neurology [verbar] Geriatrics.
Development Stage: Pre-clinical (in vivo validation).
Publications: Scerba MT, et al. 2-(Piperidin-3-yl)phthalimides
reduce classical markers of cellular inflammation in LPS-challenged RAW
264.7 cells and also demonstrate potentially relevant sigma and
serotonin receptor affinity in membrane preparations. (PMID 38996940).
Patents: PCT/US2025/034951, filed June 6, 2025.
Potential Commercial Applications:
<bullet> Neurodegenerative diseases.
<bullet> Inflammatory disorders.
<bullet> Autoimmune disorders.
<bullet> Viral infections.
<bullet> Cancer.
Competitive Advantages:
<bullet> Enhanced chemical stability and solubility.
<bullet> Greater anti-inflammatory activity.
<bullet> Potentially clinically safer than classic IMiDs by lower
risk of fetal malformations.
Collaboration Opportunity: Researchers at the NIA seek licensing
and/or co-development research collaborations for the pre-clinical and
clinical development of the compounds as anti-inflammatory therapeutics
for systemic degenerative and neurodegenerative disorders.
Dated: June 10, 2026.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2026-11996 Filed 6-12-26; 8:45 am]
BILLING CODE 4167-05-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 15, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.